Loading…
The OMERACT Giant cell arteritis Ultrasonography Score: a potential predictive outcome to assess the risk of relapse during follow-up
To determine whether the OMERACT giant cell arteritis (GCA) Ultrasonography (US) Score (OGUS) change after treatment can be used for assessing the probability of relapse. Multicenter retrospective study of GCA patients referred to two US GCA fast-track clinics over 2 years. Patients underwent US eva...
Saved in:
| Published in: | Rheumatology (Oxford, England) England), 2024-05 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | |
| container_issue | |
| container_start_page | |
| container_title | Rheumatology (Oxford, England) |
| container_volume | |
| creator | Molina-Collada, Juan Monjo-Henry, Irene Fernández-Fernández, Elisa Álvaro-Gracia, José María de Miguel, Eugenio |
| description | To determine whether the OMERACT giant cell arteritis (GCA) Ultrasonography (US) Score (OGUS) change after treatment can be used for assessing the probability of relapse.
Multicenter retrospective study of GCA patients referred to two US GCA fast-track clinics over 2 years. Patients underwent US evaluation at baseline, 3 and 6 months. EULAR definitions for remission and relapse were checked at 3 and 6 months. OGUS changes at 0-3 months and 0-6 months were compared among patients with and without relapse at 6 months, as well as those with and without remission at 6 months.
A total of 76 patients were included (mean age 77.2 years, 55.3% females). Nineteen (26%) patients relapsed at 6-months, of whom 14(19.1%) showed a minor relapse. EULAR remission at 6 months was achieved by 32(43.8%) patients. The standardized mean difference of OGUS between baseline and 3 and 6 months was -0.25 and -0.38, respectively. OGUS significantly improved between baseline and 6 months (1.18 vs 0.99,p=0.004) and from 3-6 months (1.08 vs 0.99,p=0.04) in non-relapsing patients, whereas no significant changes at 3 (1.17 vs 1.17;p=0.736) and 6 (1.17 vs 1.21;p=0.343) months were observed in those who experienced relapse. Mean 0-6-month OGUS improvement was lower in patients who relapsed (-0.1 vs 0.16,p=0.037). Mean 0-6-month OGUS improvement was greater in patients who achieved remission at 6 months (0.28vs -0.07,p=0.001).
The absence of OGUS improvement during follow-up in GCA may be used to assess the probability of relapse and the absence of remission at 6 months. |
| doi_str_mv | 10.1093/rheumatology/keae260 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3053137828</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3053137828</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1012-898b62d97fbdbea381d3a7e15e0efdbbd273c7cd9599524e839da23712b2d6183</originalsourceid><addsrcrecordid>eNpNkc1OwzAQhC0EolB4A4T2yCXgn6ZxuKGKP6moEpRz5MSb1tSJg-2A-gC8N1SUitPuYWZHOx8hZ4xeMpqLK7_EvlHRWbdYX61QIR_TPXLERmOeUCH4_m7nowE5DuGNUpoyIQ_JQMiMSSb5EfmaLxFmT7fPN5M53BvVRqjQWlA-ojfRBHi10avgWrfwqluu4aVyHq9BQecittEoC51HbapoPhBcHyvXIEQHKgQMAeJPgDdhBa4Gj1Z1AUH33rQLqJ217jPpuxNyUCsb8HQ7h-T17nY-eUims_vHyc00qRhlPJG5LMdc51ld6hKVkEwLlSFLkWKty1LzTFRZpfM0z1M-QilyrbjIGC-5HjMphuTi927n3XuPIRaNCZt_VYuuD4WgqWAik3wjHf1KK-9C8FgXnTeN8uuC0WIDoPgPoNgC-LGdbxP6skG9M_01Lr4BO4-JFQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3053137828</pqid></control><display><type>article</type><title>The OMERACT Giant cell arteritis Ultrasonography Score: a potential predictive outcome to assess the risk of relapse during follow-up</title><source>Oxford Academic</source><creator>Molina-Collada, Juan ; Monjo-Henry, Irene ; Fernández-Fernández, Elisa ; Álvaro-Gracia, José María ; de Miguel, Eugenio</creator><creatorcontrib>Molina-Collada, Juan ; Monjo-Henry, Irene ; Fernández-Fernández, Elisa ; Álvaro-Gracia, José María ; de Miguel, Eugenio</creatorcontrib><description>To determine whether the OMERACT giant cell arteritis (GCA) Ultrasonography (US) Score (OGUS) change after treatment can be used for assessing the probability of relapse.
Multicenter retrospective study of GCA patients referred to two US GCA fast-track clinics over 2 years. Patients underwent US evaluation at baseline, 3 and 6 months. EULAR definitions for remission and relapse were checked at 3 and 6 months. OGUS changes at 0-3 months and 0-6 months were compared among patients with and without relapse at 6 months, as well as those with and without remission at 6 months.
A total of 76 patients were included (mean age 77.2 years, 55.3% females). Nineteen (26%) patients relapsed at 6-months, of whom 14(19.1%) showed a minor relapse. EULAR remission at 6 months was achieved by 32(43.8%) patients. The standardized mean difference of OGUS between baseline and 3 and 6 months was -0.25 and -0.38, respectively. OGUS significantly improved between baseline and 6 months (1.18 vs 0.99,p=0.004) and from 3-6 months (1.08 vs 0.99,p=0.04) in non-relapsing patients, whereas no significant changes at 3 (1.17 vs 1.17;p=0.736) and 6 (1.17 vs 1.21;p=0.343) months were observed in those who experienced relapse. Mean 0-6-month OGUS improvement was lower in patients who relapsed (-0.1 vs 0.16,p=0.037). Mean 0-6-month OGUS improvement was greater in patients who achieved remission at 6 months (0.28vs -0.07,p=0.001).
The absence of OGUS improvement during follow-up in GCA may be used to assess the probability of relapse and the absence of remission at 6 months.</description><identifier>ISSN: 1462-0324</identifier><identifier>EISSN: 1462-0332</identifier><identifier>DOI: 10.1093/rheumatology/keae260</identifier><identifier>PMID: 38718182</identifier><language>eng</language><publisher>England</publisher><ispartof>Rheumatology (Oxford, England), 2024-05</ispartof><rights>The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-1628-5042 ; 0000-0002-0343-3747 ; 0000-0001-5191-7802 ; 0000-0002-3252-8016 ; 0000-0001-5146-1964</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38718182$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Molina-Collada, Juan</creatorcontrib><creatorcontrib>Monjo-Henry, Irene</creatorcontrib><creatorcontrib>Fernández-Fernández, Elisa</creatorcontrib><creatorcontrib>Álvaro-Gracia, José María</creatorcontrib><creatorcontrib>de Miguel, Eugenio</creatorcontrib><title>The OMERACT Giant cell arteritis Ultrasonography Score: a potential predictive outcome to assess the risk of relapse during follow-up</title><title>Rheumatology (Oxford, England)</title><addtitle>Rheumatology (Oxford)</addtitle><description>To determine whether the OMERACT giant cell arteritis (GCA) Ultrasonography (US) Score (OGUS) change after treatment can be used for assessing the probability of relapse.
Multicenter retrospective study of GCA patients referred to two US GCA fast-track clinics over 2 years. Patients underwent US evaluation at baseline, 3 and 6 months. EULAR definitions for remission and relapse were checked at 3 and 6 months. OGUS changes at 0-3 months and 0-6 months were compared among patients with and without relapse at 6 months, as well as those with and without remission at 6 months.
A total of 76 patients were included (mean age 77.2 years, 55.3% females). Nineteen (26%) patients relapsed at 6-months, of whom 14(19.1%) showed a minor relapse. EULAR remission at 6 months was achieved by 32(43.8%) patients. The standardized mean difference of OGUS between baseline and 3 and 6 months was -0.25 and -0.38, respectively. OGUS significantly improved between baseline and 6 months (1.18 vs 0.99,p=0.004) and from 3-6 months (1.08 vs 0.99,p=0.04) in non-relapsing patients, whereas no significant changes at 3 (1.17 vs 1.17;p=0.736) and 6 (1.17 vs 1.21;p=0.343) months were observed in those who experienced relapse. Mean 0-6-month OGUS improvement was lower in patients who relapsed (-0.1 vs 0.16,p=0.037). Mean 0-6-month OGUS improvement was greater in patients who achieved remission at 6 months (0.28vs -0.07,p=0.001).
The absence of OGUS improvement during follow-up in GCA may be used to assess the probability of relapse and the absence of remission at 6 months.</description><issn>1462-0324</issn><issn>1462-0332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpNkc1OwzAQhC0EolB4A4T2yCXgn6ZxuKGKP6moEpRz5MSb1tSJg-2A-gC8N1SUitPuYWZHOx8hZ4xeMpqLK7_EvlHRWbdYX61QIR_TPXLERmOeUCH4_m7nowE5DuGNUpoyIQ_JQMiMSSb5EfmaLxFmT7fPN5M53BvVRqjQWlA-ojfRBHi10avgWrfwqluu4aVyHq9BQecittEoC51HbapoPhBcHyvXIEQHKgQMAeJPgDdhBa4Gj1Z1AUH33rQLqJ217jPpuxNyUCsb8HQ7h-T17nY-eUims_vHyc00qRhlPJG5LMdc51ld6hKVkEwLlSFLkWKty1LzTFRZpfM0z1M-QilyrbjIGC-5HjMphuTi927n3XuPIRaNCZt_VYuuD4WgqWAik3wjHf1KK-9C8FgXnTeN8uuC0WIDoPgPoNgC-LGdbxP6skG9M_01Lr4BO4-JFQ</recordid><startdate>20240508</startdate><enddate>20240508</enddate><creator>Molina-Collada, Juan</creator><creator>Monjo-Henry, Irene</creator><creator>Fernández-Fernández, Elisa</creator><creator>Álvaro-Gracia, José María</creator><creator>de Miguel, Eugenio</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1628-5042</orcidid><orcidid>https://orcid.org/0000-0002-0343-3747</orcidid><orcidid>https://orcid.org/0000-0001-5191-7802</orcidid><orcidid>https://orcid.org/0000-0002-3252-8016</orcidid><orcidid>https://orcid.org/0000-0001-5146-1964</orcidid></search><sort><creationdate>20240508</creationdate><title>The OMERACT Giant cell arteritis Ultrasonography Score: a potential predictive outcome to assess the risk of relapse during follow-up</title><author>Molina-Collada, Juan ; Monjo-Henry, Irene ; Fernández-Fernández, Elisa ; Álvaro-Gracia, José María ; de Miguel, Eugenio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1012-898b62d97fbdbea381d3a7e15e0efdbbd273c7cd9599524e839da23712b2d6183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Molina-Collada, Juan</creatorcontrib><creatorcontrib>Monjo-Henry, Irene</creatorcontrib><creatorcontrib>Fernández-Fernández, Elisa</creatorcontrib><creatorcontrib>Álvaro-Gracia, José María</creatorcontrib><creatorcontrib>de Miguel, Eugenio</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Rheumatology (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Molina-Collada, Juan</au><au>Monjo-Henry, Irene</au><au>Fernández-Fernández, Elisa</au><au>Álvaro-Gracia, José María</au><au>de Miguel, Eugenio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The OMERACT Giant cell arteritis Ultrasonography Score: a potential predictive outcome to assess the risk of relapse during follow-up</atitle><jtitle>Rheumatology (Oxford, England)</jtitle><addtitle>Rheumatology (Oxford)</addtitle><date>2024-05-08</date><risdate>2024</risdate><issn>1462-0324</issn><eissn>1462-0332</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>To determine whether the OMERACT giant cell arteritis (GCA) Ultrasonography (US) Score (OGUS) change after treatment can be used for assessing the probability of relapse.
Multicenter retrospective study of GCA patients referred to two US GCA fast-track clinics over 2 years. Patients underwent US evaluation at baseline, 3 and 6 months. EULAR definitions for remission and relapse were checked at 3 and 6 months. OGUS changes at 0-3 months and 0-6 months were compared among patients with and without relapse at 6 months, as well as those with and without remission at 6 months.
A total of 76 patients were included (mean age 77.2 years, 55.3% females). Nineteen (26%) patients relapsed at 6-months, of whom 14(19.1%) showed a minor relapse. EULAR remission at 6 months was achieved by 32(43.8%) patients. The standardized mean difference of OGUS between baseline and 3 and 6 months was -0.25 and -0.38, respectively. OGUS significantly improved between baseline and 6 months (1.18 vs 0.99,p=0.004) and from 3-6 months (1.08 vs 0.99,p=0.04) in non-relapsing patients, whereas no significant changes at 3 (1.17 vs 1.17;p=0.736) and 6 (1.17 vs 1.21;p=0.343) months were observed in those who experienced relapse. Mean 0-6-month OGUS improvement was lower in patients who relapsed (-0.1 vs 0.16,p=0.037). Mean 0-6-month OGUS improvement was greater in patients who achieved remission at 6 months (0.28vs -0.07,p=0.001).
The absence of OGUS improvement during follow-up in GCA may be used to assess the probability of relapse and the absence of remission at 6 months.</abstract><cop>England</cop><pmid>38718182</pmid><doi>10.1093/rheumatology/keae260</doi><orcidid>https://orcid.org/0000-0002-1628-5042</orcidid><orcidid>https://orcid.org/0000-0002-0343-3747</orcidid><orcidid>https://orcid.org/0000-0001-5191-7802</orcidid><orcidid>https://orcid.org/0000-0002-3252-8016</orcidid><orcidid>https://orcid.org/0000-0001-5146-1964</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-0324 |
| ispartof | Rheumatology (Oxford, England), 2024-05 |
| issn | 1462-0324 1462-0332 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3053137828 |
| source | Oxford Academic |
| title | The OMERACT Giant cell arteritis Ultrasonography Score: a potential predictive outcome to assess the risk of relapse during follow-up |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T20%3A40%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20OMERACT%20Giant%20cell%20arteritis%20Ultrasonography%20Score:%20a%20potential%20predictive%20outcome%20to%20assess%20the%20risk%20of%20relapse%20during%20follow-up&rft.jtitle=Rheumatology%20(Oxford,%20England)&rft.au=Molina-Collada,%20Juan&rft.date=2024-05-08&rft.issn=1462-0324&rft.eissn=1462-0332&rft_id=info:doi/10.1093/rheumatology/keae260&rft_dat=%3Cproquest_cross%3E3053137828%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1012-898b62d97fbdbea381d3a7e15e0efdbbd273c7cd9599524e839da23712b2d6183%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3053137828&rft_id=info:pmid/38718182&rfr_iscdi=true |